NYSE:OMI Owens & Minor Q1 2025 Earnings Report $6.52 -0.08 (-1.14%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$6.52 0.00 (0.00%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Owens & Minor EPS ResultsActual EPS$0.23Consensus EPS $0.20Beat/MissBeat by +$0.03One Year Ago EPS$0.19Owens & Minor Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue Growth+0.70%Owens & Minor Announcement DetailsQuarterQ1 2025Date5/10/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time8:00AM ETUpcoming EarningsOwens & Minor's Q2 2025 earnings is scheduled for Friday, August 1, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Owens & Minor Q1 2025 Earnings Call TranscriptProvided by QuartrMay 8, 2025 ShareLink copied to clipboard.PresentationSkip to Participants Operator00:00:00Good day, and thank you for standing by. Operator00:00:02Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investor Relations. Jackie MarcusSenior Managing Director at Alpha IR Group00:00:47Thank you, operator. Hello, everyone, and welcome to the Owens and Minor First Quarter twenty twenty five Earnings Call. Our comments on the call will be focused on the financial results for the first quarter twenty twenty five as well as our outlook for 2025, all of which are included in today's press release. The press release along with the supplemental slides are posted on the Investor Relations section of our website. Please note that during this call, we will make forward looking statements that reflect the current views of Owens and Minor about our business, financial performance and future events. Jackie MarcusSenior Managing Director at Alpha IR Group00:01:21The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs and projections will result or be achieved. Please refer to our SEC filings for a full description of these risks and uncertainties, including the Risk Factors section of our annual report on Form 10 ks and our quarterly reports on Form 10 Q. Any forward looking statements that we make on this call or in our earnings press release are as of today, and we undertake no obligation to update these statements as a result of new information or future events, except to the extent required by applicable law. Jackie MarcusSenior Managing Director at Alpha IR Group00:02:12In our discussion today, we will refer to non GAAP financial measures and believe they might help investors to better understand our performance or business trends. Information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Ed Pesica, Owens and Minor's President and Chief Executive Officer and John Leon, the company's Chief Financial Officer. I will now turn the call over to Ed. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:02:40Thank you, Jackie. Good morning, everyone, and thank you for joining us on the call today. We hit the ground running in 2025, and we continue to progress forward on our broader long term strategy. Starting with our Patient Direct segment. We've had a tremendous start to the year. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:02:58Our top line grew in the mid single digits in the first quarter and our operating income grew by 31% or $14,000,000 resulting in a 173 basis point expansion. This exceptional performance was supported by many items. Let me share a few of them with you. Over the last year, we made an investment in the sleep journey. The objective of the sleep journey was to streamline the new start process and improve adherence for resupply, making it easier for customers to reorder needed products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:03:34The result of this investment can be seen in the first quarter results, which showed a meaningful increase in our sleep starts and high single digit revenue growth in our sleep supplies for the first quarter. In addition, over the last year, we've invested in additional commercial resources. This has enabled us to streamline territories while expanding the sales reps' bag, resulting in double digit growth in three categories: wound supplies, ostomy and urology. Additionally, we continue to identify therapy categories for expansion. For example, within home respiratory space, we launched an organic expansion into chest wall oscillation therapy. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:04:18Finally, during 2024, we began to invest in our already strong revenue cycle management process with the goal of enhancing our collection rates. These efforts began with a focus in our Byram division. I am pleased to report that these efforts resulted in a record collection rate in Q1. We are now moving the learnings to our Apria division and anticipate this program will be completed by the end of the year. With respect to our planned acquisition of RoTEK, we are awaiting a final decision from the regulators and still expect to close in the first half of twenty twenty five. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:04:55We have our financing in place and we are ready to move forward. Moving on to our Products and Healthcare Services segment. As a reminder, in February, we disclosed that we entered discussions regarding the potential sale of our Products and Healthcare Services segment. We remain actively engaged with a number of parties in the sale process for this segment, and I look forward to providing more information when it is prudent to do so. In the meantime, we continue to run this segment with the same level of commitment and attention to detail around serving our customers and delivering high quality products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:05:32I also recognize that the sale process creates a bit of distraction in the day to day execution. Despite the effort needed to move the sale process forward, there were some great accomplishments in the quarter. Within our Medical Distribution division, we saw continued growth in same store sales and an increase in proprietary product penetration. In addition, we have begun our distribution network automation efforts to drive long term efficiencies. We successfully opened a new state of the art distribution center in Morgantown, West Virginia to serve the state of West Virginia and surrounding areas, anchored by a long term agreement with WVU. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:06:15We also recently opened another distribution center in Sioux Falls, South Dakota to serve the Upper Midwest. Finally, let me address tariffs. I will start by saying that at Owens and Minor, we are dedicated to delivering high quality medical products to support patient care. To date, we have worked extremely hard to mitigate the impact of tariffs to our customers through cost reductions, investment in inventory, utilization of our U. S. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:06:44Manufacturing footprint, our multi country sourcing approach as well as offering un tariff product substitutions. However, in a business that operates at less than 1% profit margin, we can no longer absorb these costs. The costs absorbed to date include the 2024 tariffs on Chinese facial protection and gloves ranging from 25% to 50%. The tariffs implemented in March and April of this year ranging from 145% for imports from China to 25% for non USMCA imports from Mexico and Canada and 10% or more for imports from most other countries. We anticipate the annual exposure of current tariffs on our products to be in the range of $100,000,000 to $150,000,000 Accordingly, we are currently beginning to implement price increases in our P and HS segment that will be effective in early June. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:07:43We have elected to impact only products affected by tariffs and not blend or use a weighted average method to spread tariffs across product categories. That said, we are using our diverse manufacturing footprint and our strategic sourcing options to offer our customer alternative products with lesser impact from tariffs. Our primary goal is to ensure our customers receive the high quality and critical supplies and services that their providers and patients rely on every day. I'm excited about what's ahead for our company, and I will now turn the call over to John to discuss our financial performance in the first quarter. John? Jon LeonEVP & CFO at Owens & Minor00:08:22Thanks, Ed, and good morning, everyone. As we walk through details of the quarter and discuss the outlook for the business, please note that my remarks on today's call will cover only non GAAP financial measures. All GAAP to non GAAP financial reconciliations can be found in the press release filed earlier this morning. Now let's turn to our first quarter results. The business delivered on almost all of our expectations and the Patient Direct segment performed exceedingly well. Jon LeonEVP & CFO at Owens & Minor00:08:52Our revenue for the quarter was $2,600,000,000 up just under 1% as reported, but up 2.3% compared to the prior year on a same days basis noting that there was one less selling day in Q1 twenty twenty five versus 2024. Patient direct revenue of six seventy four million dollars grew by 6% compared to the first quarter of twenty twenty four. On a same days basis, the year over year growth was 7.3%. I am pleased to say that almost every therapy category showed good growth and sleep supplies and diabetes once again led the way. Smaller categories like Ostomy, Wound and Urology also performed very well. Jon LeonEVP & CFO at Owens & Minor00:09:36We were encouraged by the continued improvement in oxygen therapy growth, which began in the fourth quarter and feel comfortable saying that we have seen the bottom for that category and expect growth throughout 2025. The reported revenue for the Products and Healthcare Services segment showed a decline of 0.8%, while on a same sales day basis grew 0.7% compared to the first quarter last year. Segment revenue totaled $1,960,000,000 for the quarter. The Medical Distribution division again showed good same store sales, but lower year over year glove prices and lower international sales offset the Med Distribution same store sales growth. We were encouraged to again see an increase in the amount of our proprietary product sales running through our distribution channel, a key strategic initiative of ours. Jon LeonEVP & CFO at Owens & Minor00:10:32Gross profit in the first quarter was $526,000,000 or 20% of net revenue. Although gross margin expanded by 40 basis points in patient direct, a rise in commodity input costs, particularly nitrile, and an abnormally large and adverse change in foreign currency rates within PNHS drove the consolidated gross margin rate down by about 50 basis points. Our distribution, selling and administrative expenses for the quarter were $462,000,000 or 17.6% of revenue compared to $478,000,000 in last year's first quarter, was 18.3% of revenue. Lower benefits costs and focused expense reduction and efficiency efforts drove the improvement in DS and A. These lower expenses were partially offset by costs related to the build out of our two new state of the art medical distribution facilities. Jon LeonEVP & CFO at Owens & Minor00:11:27Adjusted operating income was $61,000,000 in the first quarter, an improvement of about 7% versus Q1 twenty twenty four. This included 31% segment operating income growth at Patient Direct. The Products and Healthcare Services segment realized a larger impact from foreign currency in the first quarter than we usually see and this negatively impacted consolidated adjusted operating income by $3,000,000 Interest expense in the first quarter was just under $34,000,000 down $1,700,000 compared to the prior year's first quarter. This change was driven by lower average borrowings throughout the course of the quarter, partially offset by less interest income than we had in the first quarter of twenty twenty four. Our adjusted effective tax rate was 31.9% as compared to 29.2% in the first quarter last year. Jon LeonEVP & CFO at Owens & Minor00:12:16The increase is primarily due to the impact of a lower share price on equity compensation. Adjusted net income for the quarter was $18,000,000 or $0.23 per share compared to $15,000,000 or $0.19 per share last year, representing about 20% growth. Adjusted EBITDA grew 5% to $122,000,000 versus $116,000,000 reported during the first quarter of twenty twenty four. As expected and discussed last quarter, we have what we believe will be the weakest cash flow quarter of the year. The consumption of working capital was driven by a number of factors, none larger than increase in products and healthcare services inventory ahead of the opening of the previously mentioned new distribution centers as well as in anticipation of tariffs. Jon LeonEVP & CFO at Owens & Minor00:13:05Additionally, the first quarter always marks the payment of incentive compensation to a number of our teammates. And this year, due to the timing of payroll at the end of the first quarter, accrued salaries declined by $22,000,000 as compared to year end. Also, cash expenses related to both the planned Roadtec acquisition and the potential sale of the Products and Healthcare Services segment totaled approximately 23,000,000 Cash outlays from most of these items are expected to reduce over the course of the year. This fact, along with the seasonal profit growth and seasonal improvement in the already best in class collection rates of Patient Direct, should lead to marked improvement in cash flow, which will be used for debt reduction as we continue to focus on returning to the targeted leverage debt range of two to three times EBITDA. As you heard from Ed, we're actively making pricing changes to pass along the impact of tariffs in addition to reworking sourcing strategies. Jon LeonEVP & CFO at Owens & Minor00:14:02We also are prepared to leverage our U. S. Manufacturing footprint. The vast preponderance of potential tariff exposure resides in products and healthcare services and the margin profile of that business obviously makes any tariff absorption impossible. While we believe we will be well positioned to protect the business from a tariff impact, the possibility exists of at least an adverse timing impact on working capital as tariffs are paid ahead of AR collections. Jon LeonEVP & CFO at Owens & Minor00:14:32Importantly, as noted in this morning's press release, we have reaffirmed guidance for the year and continue to expect improving results in each subsequent quarter and we still see at least 70% of earnings and cash flow generated in the second half of the year. Overall, it's pleasing to have the business start the year largely as expected and we remain bullish on the outlook for earnings and cash flow for the remainder of 2025. I'll now turn the call over to the operator for questions. Operator? Operator00:15:02Thank you. We will now begin the question and answer session. Operator00:15:14Session. Operator00:15:36Your first question comes from the line of John Stansell of JPMorgan. Your line is now open. John StanselVP - Equity Research at JP Morgan00:15:44Great. Thanks for taking the question. Just want to dig in on the tariff side of this. Can you just talk about the discussions you're having with your customers and how they are or not planning around this potentially changing behavior or approaching their sourcing? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:05Yeah. Sure, John. Excuse me. Sorry. So let me again rescope the tariff exposure. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:11We think it's in the 100,000,000 to $150,000,000 range. We think it's as of right now, it's on that lower end of the range. But obviously, as product mix changes, that could change. That's why we have the range on it. And the bulk of ours is really coming from China and Thailand, obviously, where we make our gloves and then some of the sourcing of more of the commodity type products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:32And smaller, very small impact really related to USMCA type products coming from Mexico. Regarding our customers, look, we've got various contractual opportunities or contractual ability to be able to adjust prices going forward. We recognize from a customer standpoint, it's a difficult conversation. We've done, I think, really a good job over the last several months absorbing a significant portion of it. Again, as a reminder, there were tariffs that went on facial protection as well as gloves that were effective at the end of last year as well as in January 1, plus the additionals. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:17:10Some of the things we've done to help mitigate that for our customers as we increased our inventory significantly in the first quarter of the year to make sure we have product on on hand. You know, but then again, you know, at 1% selling margin in this business, we can't afford to take on, you know, a 45% tariff, and we have to work together with our customers, you know, to work through that. You know, we are working with our customers to identify alternatives, you know, products that can be substituted out at a lower cost, But that's those are the conversations we're we're having and we'll have going forward. I think the other thing we're trying to do is because this is such an administrative burden for customers and they're getting it from various suppliers, not just us, is to try to do it infrequently so you don't have, you know, so much administrative work associated with it. So that's where we are in the process, you know, and it's a pretty fluid environment too. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:18:08But, you we're gonna have the ability to react as things change within the policies and the tariffs. And that's the way we're approaching it. John StanselVP - Equity Research at JP Morgan00:18:20Great. And then just quickly on FX. Obviously, a headwind, it sounds like in the first quarter, the dollar has moved around a fair amount in March, April. I just you reaffirmed FX, I think, as of the end of last year. Just how should we think about the impact progressing through the remainder of the year versus your expectations? Jon LeonEVP & CFO at Owens & Minor00:18:40John, it's John Lena. Yes, think we saw a lot of volatility in the dollar, particularly in the month of March, particularly in the Asian currencies where we do a lot of our manufacturing and sourcing. That has since subsided quite a bit. You're right, the dollar still moves quite a bit. But relative to what we saw in March, things are much, much calmer now. Jon LeonEVP & CFO at Owens & Minor00:18:59And we if we stay where we are today, think the guidance will be fine. We don't expect too much more volatility like we saw in March. And reminder, it's just in the P and H segment only where we see that. So, well, what we know today, think we're comfortable with the guidance for the rest of the year around FX. Operator00:19:23Your next question comes from the line of Michael Cherny of Leerink Partners. Please go ahead. Ahmed MuhammadAssociate at Leerink Partners00:19:31Good morning. This is Ahmed on for Mike Cherny. Thank you for the color that you gave on tariffs. I just wanted to clarify, is the 100,000,000 to $150,000,000 the direct impact of tariffs, or is it just the exposure, the potential exposure? And just to be clear, what exactly is embedded in the guidance? Ahmed MuhammadAssociate at Leerink Partners00:19:52And, just if there's any more color you could give there. And as you think about price increases, will you be able to preserve spread or is the goal just to preserve GP dollars? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:20:07Yeah. So the the tariff exposure in an essence, if you if you look at it at a SKU level, you try to take it to that level of detail, gone through it by country of origin, knowing what the tariff is, knowing what our product cost would go up, know, that's what it is in totality. And then from there, the expectation is that we're gonna cover those dollars that come through. So that's what we're expecting on an aggregate basis. So hopefully, that helps when I talk about the 50,000,000 exposure. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:20:36That is what is getting passed through so that way it can cover our cost increases. Operator00:20:49Your next question comes from the line of Daniel Grosslight of Citi. Please go ahead. Luismario HigueraAnalyst at Citigroup00:20:56Hey, this is Luis on for Daniel Grosslight. Just a quick follow-up. What is the split between the 100 and 1 hundred and 50 tariff exposure between the PNHS segment and the PD segment? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:08Yeah. It's virtually all PNHS segment. I mean, we've gone through in detail analysis for our patient direct segment. And within the patient direct segment, the vast majority of the products are either made in The US or qualify under the Nairobi protocol. So there is very little exposure within our patient direct segment today associated with it. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:30You know, the one areas, and it's a small category for us, you would think would be something like a bet metal area where you do have some of that stuff made overseas. But again, the 100,000,000 to $150,000,000 it's virtually all in our P and HS segment. Luismario HigueraAnalyst at Citigroup00:21:46It. Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:49Other Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:50common one sorry. I'll just add one more comment on tariffs. And, you know, again, recognizing that, you know, there's a lot of conversation we have to have with customers. But in in the industry today, we're not the only ones trying to pass this on and needing to pass it on. So really across the industry, you know, it's it's most manufacturers and or distributors and or suppliers that are needing to do this because of such the margin rates we have within the space. Operator00:22:24All right. Your next question comes from the line of Kevin Caliente of UBS. Please go ahead. Kevin CaliendoManaging Director at UBS Group00:22:33Good morning, guys. Thanks for taking my questions. First one, I just want to understand a little bit on the guidance. The RoTEK financing is in place, but, it doesn't look like the interest expense has changed. So is that like, how are you accounting for that in the guidance? Kevin CaliendoManaging Director at UBS Group00:22:51Or do you are you just not gonna is the financing set up such that it won't really start to pay until the deal closes? And so you'll update the guidance then. I just wanna understand how how that dynamic works. Jon LeonEVP & CFO at Owens & Minor00:23:05Yeah. Kevin, it's John. So the none of the debt comes on to the balance sheet until we actually close the deal. The b loan, the term B loan will begin to accrue interest before the May, keeping in mind that we are expecting to hear from the FTC in early June. So, at that point, once we hear from the FTC, then it gives us opportunity to close the deal to to re review the guidance. Jon LeonEVP & CFO at Owens & Minor00:23:31But without knowing exactly that outcome and not having the debt on the balance sheet right now, we've left the guidance alone and not impact any the the EBITDA from Rotek or the or the debt. That that makes sense to you? Kevin CaliendoManaging Director at UBS Group00:23:43Yeah. No. That that that's helpful. I know the debt came in more maybe met a higher rate than you had expected. Are any of your assumptions around, you know, Roadtec accretion changed in any way, shape, or form? Kevin CaliendoManaging Director at UBS Group00:23:58Or, you know, how should we think about that? It's not in people's models or most people's models yet, but I'm just wondering how you're thinking about it. Are you gonna just plan to update us when the deal closes? Jon LeonEVP & CFO at Owens & Minor00:24:09Yeah. Well, you'll recall that we had it neutral the first full year, then accretive in the second year. It was like ten, fifteen, so that's an exact number. But we'll certainly update upon closing. But you are correct. Jon LeonEVP & CFO at Owens & Minor00:24:21The debt came in roughly 50 basis points than we had anticipated at the time of the deal. Kevin CaliendoManaging Director at UBS Group00:24:27Okay. And just one last one on free cash flows or if I'm hogging the phone here a little bit. But on our last in the last quarter, you gave kind of a cash flow bridge, right? EBITDA with CapEx of around $260,000,000 and the interest expense guidance just remains the same. The one thing, I guess, that's different now is, obviously, the working capital looks a lot different than maybe you had anticipated. Kevin CaliendoManaging Director at UBS Group00:24:54The last commentary you made to us publicly was that there would be like 100,000,000 to $150,000,000 of cash flow available depending on working cap. Do you still anticipate, given what you did with inventory, that the free cash flow this year would be meaningful or $100,000,000 or more. Is that still in play? Jon LeonEVP & CFO at Owens & Minor00:25:15Yes, that's still in play. No change to the outlook for the cash flow. You're right, there's a lot of numbers in play this quarter. I would say most were largely anticipated. I would offer probably the cost around the strategic initiatives, both the planned RoTEK acquisition and the potential sale of P and A just a little higher than we thought, particularly on the RoTEK side. Jon LeonEVP & CFO at Owens & Minor00:25:38But other than that, it's as we expected. So there's no change in the outlook for cash flow for the year. We still expect to be able to generate good free cash flow and use it to pay down debt. Kevin CaliendoManaging Director at UBS Group00:25:47Fantastic. Thank you so much. Operator00:25:53Your next question comes from the line of Eric Caldwell of Baird. Please go ahead. Eric ColdwellSenior Research Analyst at Baird00:26:01Thanks. Good morning. I have few. I'm curious if you could share with us the incremental tariffs that you actually realized in q one from those that were all in effect and those that went into effect, January 1. What was the what was the impact on the quarter itself? Eric ColdwellSenior Research Analyst at Baird00:26:21Obviously, some of the pricing decisions hadn't gone into effect at that point on your side. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:26:27Yeah. Really didn't you know, based on the inventory we had in place, Eric, it really did not have an impact on q one. Eric ColdwellSenior Research Analyst at Baird00:26:33Okay. Good. And then the the second quarter here, the quarter that we're in, I'm I'm curious just from an easing standpoint with the models, you know, you were just asked about the, the Roadtec debt and when the financing comes in. And it sounds like maybe there could be a slight mismatch on timing on the term the term, coming in in May, but there's also the tariff, increases. And you're talking about pricing that starts to go into effect, I believe, in early June. Eric ColdwellSenior Research Analyst at Baird00:27:07So is there a bit of a gap here for a couple of months before your pricing efforts take effect? And, you know, if so, what is the what is the potential impact of tariffs here in the second quarter? Or would you be on still a a bit of a delay because of the timing of when inventory flows? Edward A. PesickaPresident, CEO & Director at Owens & Minor00:27:24Yeah. I I think at a high level, Eric, the way we think about it, way we thought about it, and the way we've done it from a timing standpoint, you know, by having the new pricing in in early June based on what the inventory and what our normal flow through should be and based on the inventory we had in the first quarter, that's when we need to start to to do it as the higher price stuff starts to flow through our system. So that timing lines up pretty pretty good on on when the products go flow through our system and when those price increases go, you know, go into effect. Eric ColdwellSenior Research Analyst at Baird00:27:57Got it. And then what happens in a scenario I I completely understand what you're saying and most others are saying in terms of having to pass the pricing on, to, you know, a large or entire extent. Some of your competitors may not pass all of the pricing on. They may use that as, you know, a bit of a competitive advantage or, take advantage of a tough situation for clients and use that to to gain share. Some manufacturers have said they're not going to raise prices or not going to raise them fully. Eric ColdwellSenior Research Analyst at Baird00:28:31And then some manufacturers have also said they're going to spread tariffs across all products and so not go SKU by SKU, country by country. So there could be some mismatch in the pricing on specific products if you're, for example, taking, you know, a 45% on a certain China product, but a competitor might be, you know, taking a lesser amount on that particular product. So we also have a hospital, and maybe more health systems that have said they're just not gonna take price increases. I mean, Vanderbilt's been pretty clear on this. So what happens, if a customer says no? Eric ColdwellSenior Research Analyst at Baird00:29:06Do you do you just lose the sale, or do you, you know, do you bend a bit? I'm just I'm just curious what happens in these situations where maybe the the pushback is is is is great. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:29:22Let me let me take there's a lot in that questionnaire. So let me just take first is the approach on tariffs. If others are blending or using a weighted average tariff approach, it's completely not aligned with what the tariffs are this were were were implemented or designed to do. So I'll give an illustrative example here. If you've got a Chinese product selling for a dollar and a US product selling for a dollar 30, and the company decides to do instead of doing the 45% tariff on that dollar product decides to just spread it at 25% across everything, that means that dollar product goes up to a dollar 25 and it's still below The US made product price. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:30:09And you're still encouraging people to buy the lower cost Chinese product. That is not the intent of the tariffs. In tariff the tariffs, you know, they're increasing costs for Chinese made products that ultimately will help lean towards buying products that are either made in The US or in tariff friendly or US friendly countries. So that's why we've taken the approach to actually implement the tariffs based on the way they have been laid out, not use not turn around and blend it and raise prices on every product regardless of where it's made. So we've taken a pretty direct approach on that. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:30:46Second of all, you know, there's requirements that that don't enable that will will stop us from selling products at a loss, you know, and we just we just can't do that, due to various requirements that are out there. You know? And I and I think with our customers, we're gonna work with them. We're gonna work with them aggressively to find them other products potentially that are lower cost than what the tariff implemented product is and and focus on that. You know, that's what we have to do because, again, what we can't do is sell products and that have significant loss on them because we're we're we're absorbing the tariff cost. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:31:25So that's the intent of what we we're gonna do with within this. Eric ColdwellSenior Research Analyst at Baird00:31:32And then the, the thank you for that. The the last one for me, Roadtec, the you you John mentioned the the debt was about 50 bps higher than originally, forecast. That that process, since you first announced the deal has been going on for, you know, nearly a year now, as you've reported in your, you know, various debt and financing presentations. As you reported over time, RoTEK's financials actually did deteriorate a bit. Revenue and margin profile came in. Eric ColdwellSenior Research Analyst at Baird00:32:09I'm curious now that a year has passed, is the acquisition target performing at the levels you built into your original base case of neutral in year one and $0.15 accretive in year two? Jon LeonEVP & CFO at Owens & Minor00:32:25Eric, it's John. Yes, the answer to question is yes. Roadtec continues to perform as we expected. 2024 came in very much right on top of our deal model. The declines that people saw were largely anticipated and largely resulted from a lot of COVID era benefits that the industry got to realize that fell off in early twenty twenty four, like '75, '20 '5 PHE going away. Jon LeonEVP & CFO at Owens & Minor00:32:51We saw the same thing in our current patient direct business. So we fully anticipated those changes in 2024 and overall ROTEK performed exactly as we expected in the deal model and doing so through the first quarter of twenty twenty five. Eric ColdwellSenior Research Analyst at Baird00:33:03Okay. Thanks very much. Operator00:33:09And that concludes our Q and A session. I will now turn the conference back over to Ed for closing remarks. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:33:17So thank you everyone. And, you know, really, appreciate you taking the time to join us this morning. You know, I'm excited about where we're going as a company. And we really have, you know, a bright future ahead of us, you know, as we continue to operate and execute on our long term strategy. With that, I look forward to sharing progress with you later this summer. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:33:36Thank you. Operator00:33:38Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read moreParticipantsExecutivesEdward A. PesickaPresident, CEO & DirectorJon LeonEVP & CFOAnalystsJackie MarcusSenior Managing Director at Alpha IR GroupJohn StanselVP - Equity Research at JP MorganAhmed MuhammadAssociate at Leerink PartnersLuismario HigueraAnalyst at CitigroupKevin CaliendoManaging Director at UBS GroupEric ColdwellSenior Research Analyst at BairdPowered by Key Takeaways Owens & Minor delivered strong Q1 results with total revenue of $2.6 billion, Patient Direct revenue up 7.3% on a same-days basis and operating income up 31%, driving adjusted EPS of $0.23, a 20% increase year-over-year. The Patient Direct segment benefitted from investments in the “sleep journey,” expanded commercial resources yielding double-digit growth in wound supplies, ostomy and urology, new therapy category launches, and a record collection rate that will be extended across divisions by year-end. Management is awaiting final regulatory approval for the RoTEK acquisition (expected H1 2025) with financing secured, while actively pursuing the sale of its Products & Healthcare Services segment alongside ongoing distribution network automation and new state-of-the-art distribution centers. Amid escalating tariffs—which could cost $100–150 million annually—Owens & Minor will implement targeted price increases on affected Products & Healthcare Services SKUs in early June, supported by US manufacturing and diversified sourcing to mitigate customer impact. Q1 represented the company’s weakest cash flow due to inventory buildup for new distribution centers and tariff preparation, but management has reaffirmed full-year guidance, expects cash flow and earnings to improve each quarter, and plans to use excess cash to reduce debt toward a 2–3× EBITDA leverage target. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallOwens & Minor Q1 202500:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipants Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Owens & Minor Earnings HeadlinesOwens & Minor: FTC Approval And Stock Repurchases Could Trigger The Stock PriceMay 26 at 3:37 PM | seekingalpha.comAnalysts Set Owens & Minor, Inc. (NYSE:OMI) Target Price at $12.50May 23, 2025 | americanbankingnews.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 29, 2025 | Timothy Sykes (Ad)Owens & Minor shareholders approve board appointmentsMay 18, 2025 | uk.investing.comOwens & Minor Shareholders Approve Key Governance DecisionsMay 16, 2025 | tipranks.comCautious Outlook on Owens & Minor: Sell Rating Amidst Segment Challenges and Tariff UncertaintiesMay 11, 2025 | tipranks.comSee More Owens & Minor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Owens & Minor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Owens & Minor and other key companies, straight to your email. Email Address About Owens & MinorOwens & Minor (NYSE:OMI) is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.View Owens & Minor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again? Upcoming Earnings CrowdStrike (6/3/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)PepsiCo (7/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Good day, and thank you for standing by. Operator00:00:02Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investor Relations. Jackie MarcusSenior Managing Director at Alpha IR Group00:00:47Thank you, operator. Hello, everyone, and welcome to the Owens and Minor First Quarter twenty twenty five Earnings Call. Our comments on the call will be focused on the financial results for the first quarter twenty twenty five as well as our outlook for 2025, all of which are included in today's press release. The press release along with the supplemental slides are posted on the Investor Relations section of our website. Please note that during this call, we will make forward looking statements that reflect the current views of Owens and Minor about our business, financial performance and future events. Jackie MarcusSenior Managing Director at Alpha IR Group00:01:21The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs and projections will result or be achieved. Please refer to our SEC filings for a full description of these risks and uncertainties, including the Risk Factors section of our annual report on Form 10 ks and our quarterly reports on Form 10 Q. Any forward looking statements that we make on this call or in our earnings press release are as of today, and we undertake no obligation to update these statements as a result of new information or future events, except to the extent required by applicable law. Jackie MarcusSenior Managing Director at Alpha IR Group00:02:12In our discussion today, we will refer to non GAAP financial measures and believe they might help investors to better understand our performance or business trends. Information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Ed Pesica, Owens and Minor's President and Chief Executive Officer and John Leon, the company's Chief Financial Officer. I will now turn the call over to Ed. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:02:40Thank you, Jackie. Good morning, everyone, and thank you for joining us on the call today. We hit the ground running in 2025, and we continue to progress forward on our broader long term strategy. Starting with our Patient Direct segment. We've had a tremendous start to the year. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:02:58Our top line grew in the mid single digits in the first quarter and our operating income grew by 31% or $14,000,000 resulting in a 173 basis point expansion. This exceptional performance was supported by many items. Let me share a few of them with you. Over the last year, we made an investment in the sleep journey. The objective of the sleep journey was to streamline the new start process and improve adherence for resupply, making it easier for customers to reorder needed products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:03:34The result of this investment can be seen in the first quarter results, which showed a meaningful increase in our sleep starts and high single digit revenue growth in our sleep supplies for the first quarter. In addition, over the last year, we've invested in additional commercial resources. This has enabled us to streamline territories while expanding the sales reps' bag, resulting in double digit growth in three categories: wound supplies, ostomy and urology. Additionally, we continue to identify therapy categories for expansion. For example, within home respiratory space, we launched an organic expansion into chest wall oscillation therapy. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:04:18Finally, during 2024, we began to invest in our already strong revenue cycle management process with the goal of enhancing our collection rates. These efforts began with a focus in our Byram division. I am pleased to report that these efforts resulted in a record collection rate in Q1. We are now moving the learnings to our Apria division and anticipate this program will be completed by the end of the year. With respect to our planned acquisition of RoTEK, we are awaiting a final decision from the regulators and still expect to close in the first half of twenty twenty five. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:04:55We have our financing in place and we are ready to move forward. Moving on to our Products and Healthcare Services segment. As a reminder, in February, we disclosed that we entered discussions regarding the potential sale of our Products and Healthcare Services segment. We remain actively engaged with a number of parties in the sale process for this segment, and I look forward to providing more information when it is prudent to do so. In the meantime, we continue to run this segment with the same level of commitment and attention to detail around serving our customers and delivering high quality products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:05:32I also recognize that the sale process creates a bit of distraction in the day to day execution. Despite the effort needed to move the sale process forward, there were some great accomplishments in the quarter. Within our Medical Distribution division, we saw continued growth in same store sales and an increase in proprietary product penetration. In addition, we have begun our distribution network automation efforts to drive long term efficiencies. We successfully opened a new state of the art distribution center in Morgantown, West Virginia to serve the state of West Virginia and surrounding areas, anchored by a long term agreement with WVU. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:06:15We also recently opened another distribution center in Sioux Falls, South Dakota to serve the Upper Midwest. Finally, let me address tariffs. I will start by saying that at Owens and Minor, we are dedicated to delivering high quality medical products to support patient care. To date, we have worked extremely hard to mitigate the impact of tariffs to our customers through cost reductions, investment in inventory, utilization of our U. S. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:06:44Manufacturing footprint, our multi country sourcing approach as well as offering un tariff product substitutions. However, in a business that operates at less than 1% profit margin, we can no longer absorb these costs. The costs absorbed to date include the 2024 tariffs on Chinese facial protection and gloves ranging from 25% to 50%. The tariffs implemented in March and April of this year ranging from 145% for imports from China to 25% for non USMCA imports from Mexico and Canada and 10% or more for imports from most other countries. We anticipate the annual exposure of current tariffs on our products to be in the range of $100,000,000 to $150,000,000 Accordingly, we are currently beginning to implement price increases in our P and HS segment that will be effective in early June. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:07:43We have elected to impact only products affected by tariffs and not blend or use a weighted average method to spread tariffs across product categories. That said, we are using our diverse manufacturing footprint and our strategic sourcing options to offer our customer alternative products with lesser impact from tariffs. Our primary goal is to ensure our customers receive the high quality and critical supplies and services that their providers and patients rely on every day. I'm excited about what's ahead for our company, and I will now turn the call over to John to discuss our financial performance in the first quarter. John? Jon LeonEVP & CFO at Owens & Minor00:08:22Thanks, Ed, and good morning, everyone. As we walk through details of the quarter and discuss the outlook for the business, please note that my remarks on today's call will cover only non GAAP financial measures. All GAAP to non GAAP financial reconciliations can be found in the press release filed earlier this morning. Now let's turn to our first quarter results. The business delivered on almost all of our expectations and the Patient Direct segment performed exceedingly well. Jon LeonEVP & CFO at Owens & Minor00:08:52Our revenue for the quarter was $2,600,000,000 up just under 1% as reported, but up 2.3% compared to the prior year on a same days basis noting that there was one less selling day in Q1 twenty twenty five versus 2024. Patient direct revenue of six seventy four million dollars grew by 6% compared to the first quarter of twenty twenty four. On a same days basis, the year over year growth was 7.3%. I am pleased to say that almost every therapy category showed good growth and sleep supplies and diabetes once again led the way. Smaller categories like Ostomy, Wound and Urology also performed very well. Jon LeonEVP & CFO at Owens & Minor00:09:36We were encouraged by the continued improvement in oxygen therapy growth, which began in the fourth quarter and feel comfortable saying that we have seen the bottom for that category and expect growth throughout 2025. The reported revenue for the Products and Healthcare Services segment showed a decline of 0.8%, while on a same sales day basis grew 0.7% compared to the first quarter last year. Segment revenue totaled $1,960,000,000 for the quarter. The Medical Distribution division again showed good same store sales, but lower year over year glove prices and lower international sales offset the Med Distribution same store sales growth. We were encouraged to again see an increase in the amount of our proprietary product sales running through our distribution channel, a key strategic initiative of ours. Jon LeonEVP & CFO at Owens & Minor00:10:32Gross profit in the first quarter was $526,000,000 or 20% of net revenue. Although gross margin expanded by 40 basis points in patient direct, a rise in commodity input costs, particularly nitrile, and an abnormally large and adverse change in foreign currency rates within PNHS drove the consolidated gross margin rate down by about 50 basis points. Our distribution, selling and administrative expenses for the quarter were $462,000,000 or 17.6% of revenue compared to $478,000,000 in last year's first quarter, was 18.3% of revenue. Lower benefits costs and focused expense reduction and efficiency efforts drove the improvement in DS and A. These lower expenses were partially offset by costs related to the build out of our two new state of the art medical distribution facilities. Jon LeonEVP & CFO at Owens & Minor00:11:27Adjusted operating income was $61,000,000 in the first quarter, an improvement of about 7% versus Q1 twenty twenty four. This included 31% segment operating income growth at Patient Direct. The Products and Healthcare Services segment realized a larger impact from foreign currency in the first quarter than we usually see and this negatively impacted consolidated adjusted operating income by $3,000,000 Interest expense in the first quarter was just under $34,000,000 down $1,700,000 compared to the prior year's first quarter. This change was driven by lower average borrowings throughout the course of the quarter, partially offset by less interest income than we had in the first quarter of twenty twenty four. Our adjusted effective tax rate was 31.9% as compared to 29.2% in the first quarter last year. Jon LeonEVP & CFO at Owens & Minor00:12:16The increase is primarily due to the impact of a lower share price on equity compensation. Adjusted net income for the quarter was $18,000,000 or $0.23 per share compared to $15,000,000 or $0.19 per share last year, representing about 20% growth. Adjusted EBITDA grew 5% to $122,000,000 versus $116,000,000 reported during the first quarter of twenty twenty four. As expected and discussed last quarter, we have what we believe will be the weakest cash flow quarter of the year. The consumption of working capital was driven by a number of factors, none larger than increase in products and healthcare services inventory ahead of the opening of the previously mentioned new distribution centers as well as in anticipation of tariffs. Jon LeonEVP & CFO at Owens & Minor00:13:05Additionally, the first quarter always marks the payment of incentive compensation to a number of our teammates. And this year, due to the timing of payroll at the end of the first quarter, accrued salaries declined by $22,000,000 as compared to year end. Also, cash expenses related to both the planned Roadtec acquisition and the potential sale of the Products and Healthcare Services segment totaled approximately 23,000,000 Cash outlays from most of these items are expected to reduce over the course of the year. This fact, along with the seasonal profit growth and seasonal improvement in the already best in class collection rates of Patient Direct, should lead to marked improvement in cash flow, which will be used for debt reduction as we continue to focus on returning to the targeted leverage debt range of two to three times EBITDA. As you heard from Ed, we're actively making pricing changes to pass along the impact of tariffs in addition to reworking sourcing strategies. Jon LeonEVP & CFO at Owens & Minor00:14:02We also are prepared to leverage our U. S. Manufacturing footprint. The vast preponderance of potential tariff exposure resides in products and healthcare services and the margin profile of that business obviously makes any tariff absorption impossible. While we believe we will be well positioned to protect the business from a tariff impact, the possibility exists of at least an adverse timing impact on working capital as tariffs are paid ahead of AR collections. Jon LeonEVP & CFO at Owens & Minor00:14:32Importantly, as noted in this morning's press release, we have reaffirmed guidance for the year and continue to expect improving results in each subsequent quarter and we still see at least 70% of earnings and cash flow generated in the second half of the year. Overall, it's pleasing to have the business start the year largely as expected and we remain bullish on the outlook for earnings and cash flow for the remainder of 2025. I'll now turn the call over to the operator for questions. Operator? Operator00:15:02Thank you. We will now begin the question and answer session. Operator00:15:14Session. Operator00:15:36Your first question comes from the line of John Stansell of JPMorgan. Your line is now open. John StanselVP - Equity Research at JP Morgan00:15:44Great. Thanks for taking the question. Just want to dig in on the tariff side of this. Can you just talk about the discussions you're having with your customers and how they are or not planning around this potentially changing behavior or approaching their sourcing? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:05Yeah. Sure, John. Excuse me. Sorry. So let me again rescope the tariff exposure. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:11We think it's in the 100,000,000 to $150,000,000 range. We think it's as of right now, it's on that lower end of the range. But obviously, as product mix changes, that could change. That's why we have the range on it. And the bulk of ours is really coming from China and Thailand, obviously, where we make our gloves and then some of the sourcing of more of the commodity type products. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:16:32And smaller, very small impact really related to USMCA type products coming from Mexico. Regarding our customers, look, we've got various contractual opportunities or contractual ability to be able to adjust prices going forward. We recognize from a customer standpoint, it's a difficult conversation. We've done, I think, really a good job over the last several months absorbing a significant portion of it. Again, as a reminder, there were tariffs that went on facial protection as well as gloves that were effective at the end of last year as well as in January 1, plus the additionals. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:17:10Some of the things we've done to help mitigate that for our customers as we increased our inventory significantly in the first quarter of the year to make sure we have product on on hand. You know, but then again, you know, at 1% selling margin in this business, we can't afford to take on, you know, a 45% tariff, and we have to work together with our customers, you know, to work through that. You know, we are working with our customers to identify alternatives, you know, products that can be substituted out at a lower cost, But that's those are the conversations we're we're having and we'll have going forward. I think the other thing we're trying to do is because this is such an administrative burden for customers and they're getting it from various suppliers, not just us, is to try to do it infrequently so you don't have, you know, so much administrative work associated with it. So that's where we are in the process, you know, and it's a pretty fluid environment too. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:18:08But, you we're gonna have the ability to react as things change within the policies and the tariffs. And that's the way we're approaching it. John StanselVP - Equity Research at JP Morgan00:18:20Great. And then just quickly on FX. Obviously, a headwind, it sounds like in the first quarter, the dollar has moved around a fair amount in March, April. I just you reaffirmed FX, I think, as of the end of last year. Just how should we think about the impact progressing through the remainder of the year versus your expectations? Jon LeonEVP & CFO at Owens & Minor00:18:40John, it's John Lena. Yes, think we saw a lot of volatility in the dollar, particularly in the month of March, particularly in the Asian currencies where we do a lot of our manufacturing and sourcing. That has since subsided quite a bit. You're right, the dollar still moves quite a bit. But relative to what we saw in March, things are much, much calmer now. Jon LeonEVP & CFO at Owens & Minor00:18:59And we if we stay where we are today, think the guidance will be fine. We don't expect too much more volatility like we saw in March. And reminder, it's just in the P and H segment only where we see that. So, well, what we know today, think we're comfortable with the guidance for the rest of the year around FX. Operator00:19:23Your next question comes from the line of Michael Cherny of Leerink Partners. Please go ahead. Ahmed MuhammadAssociate at Leerink Partners00:19:31Good morning. This is Ahmed on for Mike Cherny. Thank you for the color that you gave on tariffs. I just wanted to clarify, is the 100,000,000 to $150,000,000 the direct impact of tariffs, or is it just the exposure, the potential exposure? And just to be clear, what exactly is embedded in the guidance? Ahmed MuhammadAssociate at Leerink Partners00:19:52And, just if there's any more color you could give there. And as you think about price increases, will you be able to preserve spread or is the goal just to preserve GP dollars? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:20:07Yeah. So the the tariff exposure in an essence, if you if you look at it at a SKU level, you try to take it to that level of detail, gone through it by country of origin, knowing what the tariff is, knowing what our product cost would go up, know, that's what it is in totality. And then from there, the expectation is that we're gonna cover those dollars that come through. So that's what we're expecting on an aggregate basis. So hopefully, that helps when I talk about the 50,000,000 exposure. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:20:36That is what is getting passed through so that way it can cover our cost increases. Operator00:20:49Your next question comes from the line of Daniel Grosslight of Citi. Please go ahead. Luismario HigueraAnalyst at Citigroup00:20:56Hey, this is Luis on for Daniel Grosslight. Just a quick follow-up. What is the split between the 100 and 1 hundred and 50 tariff exposure between the PNHS segment and the PD segment? Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:08Yeah. It's virtually all PNHS segment. I mean, we've gone through in detail analysis for our patient direct segment. And within the patient direct segment, the vast majority of the products are either made in The US or qualify under the Nairobi protocol. So there is very little exposure within our patient direct segment today associated with it. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:30You know, the one areas, and it's a small category for us, you would think would be something like a bet metal area where you do have some of that stuff made overseas. But again, the 100,000,000 to $150,000,000 it's virtually all in our P and HS segment. Luismario HigueraAnalyst at Citigroup00:21:46It. Thank you. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:49Other Edward A. PesickaPresident, CEO & Director at Owens & Minor00:21:50common one sorry. I'll just add one more comment on tariffs. And, you know, again, recognizing that, you know, there's a lot of conversation we have to have with customers. But in in the industry today, we're not the only ones trying to pass this on and needing to pass it on. So really across the industry, you know, it's it's most manufacturers and or distributors and or suppliers that are needing to do this because of such the margin rates we have within the space. Operator00:22:24All right. Your next question comes from the line of Kevin Caliente of UBS. Please go ahead. Kevin CaliendoManaging Director at UBS Group00:22:33Good morning, guys. Thanks for taking my questions. First one, I just want to understand a little bit on the guidance. The RoTEK financing is in place, but, it doesn't look like the interest expense has changed. So is that like, how are you accounting for that in the guidance? Kevin CaliendoManaging Director at UBS Group00:22:51Or do you are you just not gonna is the financing set up such that it won't really start to pay until the deal closes? And so you'll update the guidance then. I just wanna understand how how that dynamic works. Jon LeonEVP & CFO at Owens & Minor00:23:05Yeah. Kevin, it's John. So the none of the debt comes on to the balance sheet until we actually close the deal. The b loan, the term B loan will begin to accrue interest before the May, keeping in mind that we are expecting to hear from the FTC in early June. So, at that point, once we hear from the FTC, then it gives us opportunity to close the deal to to re review the guidance. Jon LeonEVP & CFO at Owens & Minor00:23:31But without knowing exactly that outcome and not having the debt on the balance sheet right now, we've left the guidance alone and not impact any the the EBITDA from Rotek or the or the debt. That that makes sense to you? Kevin CaliendoManaging Director at UBS Group00:23:43Yeah. No. That that that's helpful. I know the debt came in more maybe met a higher rate than you had expected. Are any of your assumptions around, you know, Roadtec accretion changed in any way, shape, or form? Kevin CaliendoManaging Director at UBS Group00:23:58Or, you know, how should we think about that? It's not in people's models or most people's models yet, but I'm just wondering how you're thinking about it. Are you gonna just plan to update us when the deal closes? Jon LeonEVP & CFO at Owens & Minor00:24:09Yeah. Well, you'll recall that we had it neutral the first full year, then accretive in the second year. It was like ten, fifteen, so that's an exact number. But we'll certainly update upon closing. But you are correct. Jon LeonEVP & CFO at Owens & Minor00:24:21The debt came in roughly 50 basis points than we had anticipated at the time of the deal. Kevin CaliendoManaging Director at UBS Group00:24:27Okay. And just one last one on free cash flows or if I'm hogging the phone here a little bit. But on our last in the last quarter, you gave kind of a cash flow bridge, right? EBITDA with CapEx of around $260,000,000 and the interest expense guidance just remains the same. The one thing, I guess, that's different now is, obviously, the working capital looks a lot different than maybe you had anticipated. Kevin CaliendoManaging Director at UBS Group00:24:54The last commentary you made to us publicly was that there would be like 100,000,000 to $150,000,000 of cash flow available depending on working cap. Do you still anticipate, given what you did with inventory, that the free cash flow this year would be meaningful or $100,000,000 or more. Is that still in play? Jon LeonEVP & CFO at Owens & Minor00:25:15Yes, that's still in play. No change to the outlook for the cash flow. You're right, there's a lot of numbers in play this quarter. I would say most were largely anticipated. I would offer probably the cost around the strategic initiatives, both the planned RoTEK acquisition and the potential sale of P and A just a little higher than we thought, particularly on the RoTEK side. Jon LeonEVP & CFO at Owens & Minor00:25:38But other than that, it's as we expected. So there's no change in the outlook for cash flow for the year. We still expect to be able to generate good free cash flow and use it to pay down debt. Kevin CaliendoManaging Director at UBS Group00:25:47Fantastic. Thank you so much. Operator00:25:53Your next question comes from the line of Eric Caldwell of Baird. Please go ahead. Eric ColdwellSenior Research Analyst at Baird00:26:01Thanks. Good morning. I have few. I'm curious if you could share with us the incremental tariffs that you actually realized in q one from those that were all in effect and those that went into effect, January 1. What was the what was the impact on the quarter itself? Eric ColdwellSenior Research Analyst at Baird00:26:21Obviously, some of the pricing decisions hadn't gone into effect at that point on your side. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:26:27Yeah. Really didn't you know, based on the inventory we had in place, Eric, it really did not have an impact on q one. Eric ColdwellSenior Research Analyst at Baird00:26:33Okay. Good. And then the the second quarter here, the quarter that we're in, I'm I'm curious just from an easing standpoint with the models, you know, you were just asked about the, the Roadtec debt and when the financing comes in. And it sounds like maybe there could be a slight mismatch on timing on the term the term, coming in in May, but there's also the tariff, increases. And you're talking about pricing that starts to go into effect, I believe, in early June. Eric ColdwellSenior Research Analyst at Baird00:27:07So is there a bit of a gap here for a couple of months before your pricing efforts take effect? And, you know, if so, what is the what is the potential impact of tariffs here in the second quarter? Or would you be on still a a bit of a delay because of the timing of when inventory flows? Edward A. PesickaPresident, CEO & Director at Owens & Minor00:27:24Yeah. I I think at a high level, Eric, the way we think about it, way we thought about it, and the way we've done it from a timing standpoint, you know, by having the new pricing in in early June based on what the inventory and what our normal flow through should be and based on the inventory we had in the first quarter, that's when we need to start to to do it as the higher price stuff starts to flow through our system. So that timing lines up pretty pretty good on on when the products go flow through our system and when those price increases go, you know, go into effect. Eric ColdwellSenior Research Analyst at Baird00:27:57Got it. And then what happens in a scenario I I completely understand what you're saying and most others are saying in terms of having to pass the pricing on, to, you know, a large or entire extent. Some of your competitors may not pass all of the pricing on. They may use that as, you know, a bit of a competitive advantage or, take advantage of a tough situation for clients and use that to to gain share. Some manufacturers have said they're not going to raise prices or not going to raise them fully. Eric ColdwellSenior Research Analyst at Baird00:28:31And then some manufacturers have also said they're going to spread tariffs across all products and so not go SKU by SKU, country by country. So there could be some mismatch in the pricing on specific products if you're, for example, taking, you know, a 45% on a certain China product, but a competitor might be, you know, taking a lesser amount on that particular product. So we also have a hospital, and maybe more health systems that have said they're just not gonna take price increases. I mean, Vanderbilt's been pretty clear on this. So what happens, if a customer says no? Eric ColdwellSenior Research Analyst at Baird00:29:06Do you do you just lose the sale, or do you, you know, do you bend a bit? I'm just I'm just curious what happens in these situations where maybe the the pushback is is is is great. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:29:22Let me let me take there's a lot in that questionnaire. So let me just take first is the approach on tariffs. If others are blending or using a weighted average tariff approach, it's completely not aligned with what the tariffs are this were were were implemented or designed to do. So I'll give an illustrative example here. If you've got a Chinese product selling for a dollar and a US product selling for a dollar 30, and the company decides to do instead of doing the 45% tariff on that dollar product decides to just spread it at 25% across everything, that means that dollar product goes up to a dollar 25 and it's still below The US made product price. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:30:09And you're still encouraging people to buy the lower cost Chinese product. That is not the intent of the tariffs. In tariff the tariffs, you know, they're increasing costs for Chinese made products that ultimately will help lean towards buying products that are either made in The US or in tariff friendly or US friendly countries. So that's why we've taken the approach to actually implement the tariffs based on the way they have been laid out, not use not turn around and blend it and raise prices on every product regardless of where it's made. So we've taken a pretty direct approach on that. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:30:46Second of all, you know, there's requirements that that don't enable that will will stop us from selling products at a loss, you know, and we just we just can't do that, due to various requirements that are out there. You know? And I and I think with our customers, we're gonna work with them. We're gonna work with them aggressively to find them other products potentially that are lower cost than what the tariff implemented product is and and focus on that. You know, that's what we have to do because, again, what we can't do is sell products and that have significant loss on them because we're we're we're absorbing the tariff cost. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:31:25So that's the intent of what we we're gonna do with within this. Eric ColdwellSenior Research Analyst at Baird00:31:32And then the, the thank you for that. The the last one for me, Roadtec, the you you John mentioned the the debt was about 50 bps higher than originally, forecast. That that process, since you first announced the deal has been going on for, you know, nearly a year now, as you've reported in your, you know, various debt and financing presentations. As you reported over time, RoTEK's financials actually did deteriorate a bit. Revenue and margin profile came in. Eric ColdwellSenior Research Analyst at Baird00:32:09I'm curious now that a year has passed, is the acquisition target performing at the levels you built into your original base case of neutral in year one and $0.15 accretive in year two? Jon LeonEVP & CFO at Owens & Minor00:32:25Eric, it's John. Yes, the answer to question is yes. Roadtec continues to perform as we expected. 2024 came in very much right on top of our deal model. The declines that people saw were largely anticipated and largely resulted from a lot of COVID era benefits that the industry got to realize that fell off in early twenty twenty four, like '75, '20 '5 PHE going away. Jon LeonEVP & CFO at Owens & Minor00:32:51We saw the same thing in our current patient direct business. So we fully anticipated those changes in 2024 and overall ROTEK performed exactly as we expected in the deal model and doing so through the first quarter of twenty twenty five. Eric ColdwellSenior Research Analyst at Baird00:33:03Okay. Thanks very much. Operator00:33:09And that concludes our Q and A session. I will now turn the conference back over to Ed for closing remarks. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:33:17So thank you everyone. And, you know, really, appreciate you taking the time to join us this morning. You know, I'm excited about where we're going as a company. And we really have, you know, a bright future ahead of us, you know, as we continue to operate and execute on our long term strategy. With that, I look forward to sharing progress with you later this summer. Edward A. PesickaPresident, CEO & Director at Owens & Minor00:33:36Thank you. Operator00:33:38Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read moreParticipantsExecutivesEdward A. PesickaPresident, CEO & DirectorJon LeonEVP & CFOAnalystsJackie MarcusSenior Managing Director at Alpha IR GroupJohn StanselVP - Equity Research at JP MorganAhmed MuhammadAssociate at Leerink PartnersLuismario HigueraAnalyst at CitigroupKevin CaliendoManaging Director at UBS GroupEric ColdwellSenior Research Analyst at BairdPowered by